Company intelligence / Profile preview

Alpharma

Bridgewater, New Jersey, United Statesalpharma.com ↗

Ownership: Private
Employees: ~3300
Development stage: Other

Overview

Alpharma developed both generic and branded specialty pharmaceuticals (notably KADIAN and EMBEDA for pain), antibiotics (bulk and specialty), and products for human and animal health, operating globally with key clinical-stage and commercial products up until its acquisition. EMBEDA (morphine sulfate/naltrexone hydrochloride) reached FDA review/approval phase for opioid misuse-resistant pain therapy.[3][4][8]

Therapeutic areas: OncologyNeurology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

King Pharmaceuticals (acquirer)Pfizer (subsequent acquirer)

Beyond the preview

Go deeper on Alpharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpharma.